Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Int Adv Otol ; 13(1): 136-139, 2017 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-27879229

RESUMO

OBJECTIVE: In this study, we aimed to detect the incidences of ototoxicity in patients with hemoglobinopathies taking deferoxamine (DFO), deferiprone, and deferasirox using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) scale to obtain more objective data. MATERIALS AND METHODS: Fifty-five transfusion-dependent patients were evaluated in this study. The NCI CTCAE scale was used to assess ototoxicity levels. The average ferritin and hemoglobin levels, the type of iron chelator, and the duration of therapy of all the patients were recorded. RESULTS: Ototoxicity was observed in 15 patients (31.9 %), all of whom were taking DFO. The median age was 19.5 (6-43) in patients without ototoxicity and 29 (16-50) in those with ototoxicity; this difference was statistically significant (p<0.05). The median ferritin and pre-tx Hb levels were 1391 ng/mL and 9.06 mg/dL, respectively, in patients with ototoxicity and 986.7 ng/mL and 9.24 mg/dL, respectively, in those without ototoxicity; these differences were not significant (p>0.05). Ototoxicity was not observed in the eight patients who used only deferasirox and deferiprone. CONCLUSION: The ototoxicity incidence with DFO at doses below 50 mg/kg/day was 27.3%. Deferiprone and deferasirox were not associated with ototoxic effects in patients taking these drugs.


Assuntos
Otopatias/induzido quimicamente , Quelantes de Ferro/efeitos adversos , Talassemia/tratamento farmacológico , Adolescente , Adulto , Terapia por Quelação/métodos , Criança , Estudos Transversais , Otopatias/diagnóstico , Otopatias/epidemiologia , Feminino , Humanos , Incidência , Quelantes de Ferro/administração & dosagem , Masculino , Pessoa de Meia-Idade , Turquia/epidemiologia
2.
Turk J Haematol ; 29(3): 270-3, 2012 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-24744672

RESUMO

Priapism affects up to 50% of all males with sickle cell disease, and there is no standard treatment. Delayed and unsuccessful treatment leads to corporal fibrosis and impotence. It is therefore necessary to determine the best treatment methods for this complication in order to offer effective interventions to all affected patients. Herein we report an 11-year-old patient with sickle cell disease that presented with priapism 72 h after onset, and was successfully treated with automated red cell exchange and hyperbaric oxygen following unsuccessful surgical and conventional interventions.

3.
J Pediatr Endocrinol Metab ; 22(12): 1179-83, 2009 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-20333880

RESUMO

Osteopetrorickets is a rare autosomal recessive disorder of osteoclast function characterized by abnormally dense bone and failure of resorption of calcified cartilage. Rickets is a paradoxical complication of osteopetrosis, resulting from the inability of the osteoclasts to maintain a normal calcium-phosphorus balance in the extracellular fluid. We report a patient with an unusual case of infantile osteopetro-rickets who was admitted with anterior fontanel bulging and was treated with haploidentical bone marrow transplantation.


Assuntos
Conservadores da Densidade Óssea/administração & dosagem , Transplante de Medula Óssea , Calcitriol/administração & dosagem , Osteopetrose/tratamento farmacológico , Raquitismo/tratamento farmacológico , Terapia Combinada , Relação Dose-Resposta a Droga , Feminino , Humanos , Lactente , Osteopetrose/diagnóstico por imagem , Radiografia , Raquitismo/diagnóstico por imagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA